Danaher (DHR) Stock Looks Reasonably Priced After Its AI Lab Launch

Danaher has moved back into focus after a period where long term shareholders saw the stock fall 15.4% over five years, and the key issue now is whether the current price properly lines up with the cash the business can generate. With fresh headlines around artificial intelligence partnerships and autonomous labs, the stock's recent swings have sharpened the question of what its cash flows are really worth today.

• Over the past 5 years the share price has declined 15.4%, which puts added weight on whether cash flow expectations still support the current market value.
• The launch of an AI powered autonomous lab at Abcam and a collaboration with Nvidia may support expectations for more efficient research workflows and potentially change the timing and scale of future cash generation.
• If you'd rather focus on earnings, this one's for you. See why Danaher's 40.4x P/E tells a different valuation story.

For investors, the debate is whether the price near US$229 for Danaher is adequately supported by the cash flows implied by a Discounted Cash Flow (DCF) view of the business.

Alongside Danaher, you can widen your watchlist with a focused screen of 33 healthcare AI stocks.

Where Does Danaher Sit on Cash Flow?

The Discounted Cash Flow (DCF) method values Danaher by estimating the cash it can return to shareholders over time and adjusting those flows back to today. On this model, the latest twelve month free cash flow sits around $5.3b, with analysts and internal estimates pointing to growing annual free cash flows through the next decade in both the explicit and terminal stages of the 2 Stage Free Cash Flow to Equity framework.

Projected free cash flows rising toward an estimated $8.3b by 2030 help explain why the DCF outcome lands broadly in line with the current share price of $229.04. The launch of an AI powered autonomous lab at Abcam feeds into this picture because it targets more efficient research output that could support those longer term cash generation assumptions if execution goes to plan. You can see the full Discounted Cash Flow breakdown, including all the underlying assumptions, by checking how analysts model Danaher’s intrinsic worth. Find out what Danaher could be worth using our Discounted Cash Flow (DCF) estimate.

The Danaher Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Danaher pick up where the valuation puzzle leaves off and explain which assumptions on growth, profitability and earnings would need to hold for the shares to be worth materially more or meaningfully less than today’s price. Each narrative links a fair value estimate to a specific storyline about Danaher's possible catalysts and key risks so you can track over time which version of the future appears to be unfolding.

One of the top community narratives on Danaher: roughly fairly valued

"Growing use of automation and AI in life sciences research, including increased orders for Beckman Life Sciences automation platforms to support autonomous labs and AI enabled drug discovery…"

Discover why this Narrative puts Danaher at roughly fairly valued.

One more question for Danaher investors that the valuation does not answer

The cash flow story only covers part of Danaher, because our broader checks have raised specific concerns that deserve your attention before you rely too heavily on the numbers. Take a closer look at 2 warning signs before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com